Home » Pfizer’s new crown oral drug was approved with conditions for the new crown drug concept, and many stocks such as Chengda Pharmaceutical broke the daily limit jqknews

Pfizer’s new crown oral drug was approved with conditions for the new crown drug concept, and many stocks such as Chengda Pharmaceutical broke the daily limit jqknews

by admin
Pfizer’s new crown oral drug was approved with conditions for the new crown drug concept, and many stocks such as Chengda Pharmaceutical broke the daily limit jqknews

byPfizerThe news of the conditional approval of the new crown oral drug was boosted, and the concept of the new crown drug broke out on the 14th. As of press time,Chengda PharmaceuticalMasamoto ChemistryPorton sharesWait for the “20cm” daily limit,Tuoxin Pharmaceuticalrose more than 14%,Shanghai KaibaoJunshi Biologyrose about 13%,Pinnacle GroupEssence Pharma“10cm” daily limit,Star Lake TechnologyHanyu Pharmaceuticalrose more than 8%.

On the news, on February 11, the State Food and Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the “Drug Administration Law” and in accordance with the special drug approval procedures, and approved conditions.PfizerThe company’s new coronavirus treatment drug nematevir tablet/ritonavir tablet combination package (namely Paxlovid) was imported and registered.

According to the official website of the State Food and Drug Administration, this product is an oral small-molecule new coronavirus treatment drug for the treatment of adults with mild to moderate new coronavirus pneumonia (COVID-19) patients with high risk factors for progression to severe disease, such as those with advanced age. , chronic kidney disease, diabetes, cardiovascular disease, chronic lung disease and other severe high-risk factors. Patients should strictly follow the instructions for medication under the guidance of physicians, and should pay close attention to the information on interactions with other drugs listed in the instructions during use.

The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner.

See also  Bringing financial water to the green economy

(Article Source:securitiesTimes Network)


Article source: Securities Times Network

Responsible editor: 33

Original title: Pfizer’s new crown oral drug was approved with conditions, the concept of new crown drug broke out, and many stocks such as Chengda Pharmaceutical Co., Ltd.

Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.

report

Share to WeChat Moments

Open WeChat,

Click “Discover” at the bottom

Use “Sweep”

You can share the webpage to the circle of friends

Scan the QR code to follow

Oriental Fortune official website WeChat

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy